Premium
Treatment of 3‐Wall Intrabony Defects in Patients With Chronic Periodontitis With Autologous Platelet‐Rich Fibrin: A Randomized Controlled Clinical Trial
Author(s) -
Sharma Anuj,
Pradeep A.R.
Publication year - 2011
Publication title -
journal of periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.036
H-Index - 156
eISSN - 1943-3670
pISSN - 0022-3492
DOI - 10.1902/jop.2011.110075
Subject(s) - medicine , platelet rich fibrin , chronic periodontitis , debridement (dental) , dentistry , periodontitis , fibrin , randomized controlled trial , radiography , surgery , bleeding on probing , gingival and periodontal pocket , clinical trial , immunology
Background: Platelet‐rich fibrin (PRF) is considered a second‐generation platelet concentrate that is widely used in osseous regeneration. The present study aims to explore the clinical and radiographic effectiveness of autologous PRF in the treatment of intrabony defects in patients with chronic periodontitis. Methods: Fifty‐six intrabony defects were treated with either autologous PRF with open‐flap debridement or open‐flap debridement alone. Clinical parameters such as the probing depth (PD) and periodontal attachment level (PAL) were recorded at baseline and 9 months postoperatively. The defect fill at baseline and 9 months was calculated on standardized radiographs by using image‐analysis software. Results: The mean PD reduction was greater in the test group (4.55 ± 1.87 mm) than in the control group (3.21 ± 1.64 mm), whereas the mean PAL gain was also greater in the test group (3.31 ± 1.76) compared to the control group (2.77 ± 1.44 mm). Furthermore, a significantly greater percentage of mean bone fill was found in the test group (48.26% ± 5.72%) compared to the control group (1.80% ± 1.56%). Conclusions: Within the limits of the present study, there was greater PD reduction, PAL gain, and bone fill at sites treated with PRF with conventional open‐flap debridement compared to conventional open‐flap debridement alone. However, a long‐term, multicentered randomized controlled clinical trial is required to know the clinical and radiographic effects of PRF on bone regeneration.